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Abstract
Foot-and-mouth disease (FMD) is a highly contagious disease of cloven-hoofed animals. It produces severe
economic losses in the livestock industry. Currently available vaccines are based on inactivated FMD virus (FMDV).
The use of empty capsids as a subunit vaccine has been reported to be a promising candidate because it avoids the
use of virus in the vaccine production and conserves the conformational epitopes of the virus. In this report, we
explored transient gene expression (TGE) in serum-free suspension-growing mammalian cells for the production of
FMDV recombinant empty capsids as a subunit vaccine. The recombinant proteins produced, assembled into empty
capsids and induced protective immune response against viral challenge in mice. Furthermore, they were recognized
by anti-FMDV bovine sera. By using this technology, we were able to achieve expression levels that are compatible
with the development of a vaccine. Thus, TGE of mammalian cells is an easy to perform, scalable and cost-effective
technology for the production of a recombinant subunit vaccine against FMDV.
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Introduction
Foot-and-mouth disease (FMD) is a highly contagious
disease of cloven-hoofed animals such as cattle, pigs, sheep
and deer. The disease is endemic in many parts of the
developing world and continues to pose a serious threat to
livestock industries. It is of economic importance because the
presence of the disease in developing countries results in
severe restrictions to international trade and an outbreak in
FMD-free countries can cause billionaire losses [1]. Prevention
and eradication of the disease in a country requires sustained
effort at significant cost. Vaccination is still a major strategy in
developing countries to control FMD [2].
Foot-and-mouth disease virus (FMDV), a member of the
family Picornaviridae, genus Aphthovirus, is a non-enveloped
single positive-sense stranded RNA virus and the etiological
agent of the disease [3]. Seven serotypes of FMDV (A, O, C,
SAT1, SAT2, SAT3 and ASIA1) and multiple subtypes within
each serotype have been described. Viral infection or
vaccination with one serotype does not confer protection
against other serotypes [4]. Thus, an update of the antigenic
composition of the vaccine is required when new field strains
appear.
The vaccine currently being used consists on chemically
inactivated virus. To produce this vaccine, suspension growing
baby hamster kidney-21 (BHK-21) cells are infected with virus
and binary ethyleneimine is subsequently used for the
inactivation process [2,5]. There are a number of
disadvantages with its use, including the need for high-
biosafety production facilities, the risk of incomplete inactivation
of the virus, the problem of discriminating between vaccinated
and infected animals and the fact that some serotypes and
subtypes have problems to grow in cell cultures [6,7]. In order
to address these problems, development of new vaccines is
needed. Recombinant empty capsids are a promising
alternative subunit vaccine against FMD because they are as
immunogenic as virions but lack the infectious nucleic acid [8,9]
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FMDV has an icosahedral capsid that is formed by the
assembly of the structural proteins VP1, VP2, VP3 and VP4.
The capsid precursor P12A is processed by the protease 3C to
produce the structural proteins VP0, VP3 and VP1. One copy
of each protein spontaneously form the protomer (5S),
subsequently five protomers form the pentamer (12S) and
finally twelve pentamers assemble into the empty capsid (75S)
[10]. Cleavage of VP0 into VP2 and VP4 occurs upon
encapsidation of genomic RNA into the empty capsids. The
assembly of higher-order structures has been shown to be
dependent on N-terminal myristoylation of the capsid precursor
[11]. Subviral particles produced during virion morphogenesis
can be isolated from infected cells and characterized by
different sedimentation coefficients in sucrose gradients.
Since natural FMDV empty capsids have been shown to be
as immunogenic as virions, a number of approaches have
reported the use of empty capsids as an alternative vaccine
either as DNA vaccines, recombinant viral vectors or subunit
vaccines expressed in the baculovirus system [12–16]. In all of
them, the assembly of structural proteins into empty capsids
seems to occur only when the structural proteins are expressed
in an adequate concentration [17,18]. The production of
recombinant FMDV empty capsids in mammalian cells has
been poorly explored, probably due to difficulties in the
isolation of high level expressing stable cell lines. The problem
with the classical means of producing recombinant proteins in
mammalian cells may be because protease 3C cleaves not
only the capsid precursor P12A but also cellular proteins
[19,20]. Indeed, attempts to generate a recombinant cell line
that stably expresses the necessary proteins for empty capsid
assembly failed repeatedly, since protease 3C impairs the
isolation of high expressing clones [21]. Transient transfection
of mammalian cells is a well known procedure commonly used
at small scale. However, during the last decade, the use of
suspension-growing mammalian cells, economic and efficient
transfection reagents and optimized expression vectors has
allowed transient gene expression (TGE) to become a simple,
scalable and powerful technology to generate large amounts of
recombinant proteins within a short time period [22,23].
Moreover, for some applications, TGE has become a
competitive alternative to the development of stable cell lines.
As the genetic selection step is avoided, the protease 3C
negative effect on cell growth does not represent a
shortcoming. The use of TGE has been reported for the
production of a subunit vaccine against respiratory syncytial
virus, expressing the viral fusion protein of the virus [24].
Moreover, it has been recently reported the use of TGE for the
generation of HIV-1 Gag virus like particles [25]. In both cases,
the development of stable cell lines is impaired because the
recombinant viral proteins are cytotoxic for cells.
In the present work, we evaluated TGE in serum-free
suspension-growing mammalian cells using polyethylenimine
(PEI) as transfection reagent for the production of a
recombinant subunit vaccine against FMD. Two strategies
were explored: transfection with the P12A3C expression
cassette and co-transfection with plasmids encoding the
individual structural proteins (VP0, VP3 and VP1). Yields
attractive for industry were achieved using the P12A3C
expression cassette. Furthermore, the recombinant empty
capsids elicited a protective immune response in mice. Thus,
TGE represents a suitable strategy for the production of FMDV
empty capsids in mammalian cells.
Materials and Methods
Ethics Statement
All the experiments involving animals were performed in
accordance to protocols approved by the INTA’s Ethical
Committee of Animal Welfare (Permit numbers: 19/2011 and
16/2011). All efforts were made to minimize suffering.
Cells and viruses
The human embryonic kidney 293 cell line stably expressing
a truncated Epstein–Barr virus Nuclear Antigen-1 (293-6E) was
grown in suspension in a serum-free F17 medium (Invitrogen,
Carsband, CA) as previously described [26]. Cells were grown
in suspension with agitation at 120 rpm in a humidified
incubator at 37°C with 5% CO2. BHK-21 cell monolayers were
maintained in Dulbecco’s modified Eagle medium (DMEM),
supplemented with 2% fetal bovine serum (FBS) in a
humidified incubator at 37°C with 5% CO2.
FMDV serotype A/Arg/01 inactivated (iFMDV) with binary
ethyleneimine and purified by sucrose gradient was used as a
positive control for protein characterization assays and to
formulate experimental vaccines. Infectious virus was obtained
from vesicles of experimentally infected cattle with passages in
BHK-21 cells and was used for viral challenge. All experiments
involving infectious virus were performed in INTA biosafety
level 3A facilities.
Plasmids
The recombinant plasmids used in this study were based on
the pTT5 vector [27].
pTT5-P12A3C and pTT5-P12A were constructed by
subcloning the P12A3C and P12A fragments from the pCI-
P12A3C and pCI-P12A by digesting the pTT5 vector and the
fragments with NheI and NotI enzymes [28].
For the generation of pTT5-VP0, pTT5-VP3 and pTT5-VP1
vectors, the corresponding genes were amplified from pTT5-
P12A with specific primers (VP0fw: AAAGCT AGC GCC ACC
ATG GGG GCT GGA CAA TCC AGC CCAG, VP0rev:
AAAGGA TCC TCA CTC TTT CGA GGG GAG CTC GCCG,
VP3fw: AAAGCT AGC GCC ACC ATG GGG ATC TTC CCT
GTC GCG TGC, VP3rev: AAAGGA TCC TCA CTG CGG TCG
GGG GTC AAT GGG GAG GC, VP1fw: AAAGAA TTC GCC
ACC ATG ACC ACC GCT ACT GGG GAA TCAG and VP1rev:
AAAGGA TCC TCA CAA AAG CTG TTT TTC GGG TGC
AATG). The PCR products were digested with specific
endonucleases and cloned into the pTT5 vector, which was
digested using the same enzymes. All genes include a Kozak
sequence located immediately upstream the start codon.
Plasmids were amplified in Escherichia coli (DH5α) grown in
Circle Grown medium (MP Biomedicals, Solon, OH),
supplemented with 50 µg/ml ampicillin. Plasmids were purified
using MAXI prep columns (Qiagen, Mississauga, ON).
A Novel Strategy for FMDV Empty Capsids Production
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Absorbances at 260 nm (A260) and 280 nm (A280) were
measured for plasmid quantification. Only plasmid preparations
with A260/ A280 ratio between 1.75 and 2.00 were used.
Transfection
Suspension-growing 293-6E cells were transiently
transfected using linear 25 kDa polyethylenimine (PEI)
(Polysciences, Warrington, PA). Two days before transfection,
cells were diluted in fresh medium at 0.45-0.5 × 106 cells/ml.
Cells were transfected with viability greater than 95%, at
densities that were between 1.5 and 2 × 106 cells/ml, the day of
transfection. Plasmid DNA and PEI were separately diluted in
complete serum free F17 medium at 1 and 2.5 µg/ml of culture
to be transfected, respectively. PEI was added dropwise to
DNA. The mixture was vortexed for 4 s and incubated at room
temperature for 3 min. The DNA: PEI mixture was then added
to the cells. Small-scale transfections were performed in six-
well plates. Large-scale transfections were performed in 2 L
shake flasks. After transfection, cells were harvested,
resuspended in lysis buffer (50 mM HEPES pH 7.4, 150 mM
NaCl, 1% Thesit, 0.5% NaDeoxycholate) and analyzed for
protein expression. Use of PEI for transfection may be covered
by existing intellectual property rights, including US Patent
6,013,240, European Patent 0,770,140, and foreign
equivalents for which further information may be obtained by
contacting licensing@polyplus-transfection.com.
Cell counts
A Cedex Analyzer (Roche, Laval, Qc) automated cell counter
was used to determine cell density and viability. The assay is
based on the trypan blue exclusion method.
Recombinant protein analyses
Cell lysates were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). Separated
proteins were transferred onto a nitrocellulose membrane,
blocked and then incubated with anti-FMDV guinea pig serum.
After several washes, membranes were incubated with
horseradish peroxidase-conjugated anti-guinea pig goat serum
(KPL). The reaction was visualized with an enhanced
chemiluminescence method. Quantification of recombinant
proteins in cell lysates was carried out by enzyme-linked
immunosorbent assay (ELISA). Microtiter plates (Immunolon II)
were coated with anti-FMDV rabbit serum (1/3000) in
carbonate-bicarbonate buffer, pH 9.6, at 4°C overnight. After
washing with PBS 0.1% Tween-20 and blocking with 1%
ovoalbumin in phosphate-buffered saline (PBS) 0.1%
Tween-20, cell lysates were added and incubated on plates at
37°C for an hour. Known amounts of purified iFMDV were two-
fold serially diluted and added to the wells for standard curve
generation. Plates were then incubated with anti-FMDV guinea
pig serum, followed by horseradish peroxidase-conjugated anti-
guinea pig goat serum (KPL). O-phenylenediamine-H2O2 was
used as substrate. The reaction was stopped with sulfuric acid
12%. Absorbance was recorded at 492 nm (A492) in a
microplate reader (Thermo Scientifics MultiskanFC).
Structural protein characterization was carried out by ELISA
using four different monoclonal antibodies (MAbs 1-5, 2-4, 3-3
and 3-2) directed to conformational epitopes of FMDV A/Arg/01
[29].
Lysate of 293-6E cells transfected with pTT5-P12A3C and
mock transfected were loaded onto a 45-15% sucrose gradient
and centrifuged at 16,500 rpm 16 h in a SW28 rotor at 4°C.
Fractions were collected and tested by ELISA. Inactivated
FMDV A/Arg/01 was run at the same conditions and used as
positive control. Absorbance of the fractions corresponding to
the virus was also measured at 260 nm.
Immunization of mice and detection of humoral
immunity
BALB/c nine-week-old male mice (School of Veterinary
Sciences, La Plata, Argentina) were randomly divided into five
groups, with seven mice in each group.
Group 1 received no treatment, group 2 received lysates of
mock transfected cells, group 3 received lysates of pTT5-
P12A3C transfected cells containing about 500 ng of
recombinant protein, group 4 received lysates of pTT5-P12A
transfected cells (the same volume of lysate as group 3) and
group 5 received 500 ng of purified FMDVi. Vaccines were
formulated with ISA206 (MONTANIDE) as adjuvant in a
proportion adjuvant: antigen 60:40. Mice were intraperitoneally
(IP) inoculated with 0.3 ml of each formulation and boosted 21
days post inoculation (dpi). Sera were collected at 14 and 28
dpi for humoral immunity analysis.
Anti-FMDV antibodies from immunized mice serum were
measured by ELISA. Immunolon II plates were coated with
anti-FMDV rabbit serum in carbonate-bicarbonate buffer, pH
9.6, at 4°C overnight. After washing and blocking, iFMDV was
added. Serial dilutions of mice serum samples were incubated
on plates for half an hour. Anti-FMDV antibodies were detected
using horseradish peroxidase-conjugated anti-mouse goat
serum. O-phenylenediamine-H2O2 was used as substrate. The
reaction was stopped with sulfuric acid 12%.
Viral challenge
Protection against FMDV was assessed as previously
described [30]. Briefly, mice were IP inoculated with 102 TCID
infectious FMDV A/Arg/01. Animals were anesthetized and
bled by retro orbital route 24 h later. Heparinized blood was
spread on BHK-21 cell monolayers. After virus adsorption,
monolayers were washed with PBS. Fresh DMEM with 2%
FBS was added and the cells were kept at 37°C for 72 h in a
5% CO2 incubator. Animals were considered protected if the
cell monolayer did not present cytopathic effect after a blind
passage. Percentage of protection was calculated as
(protected mice/challenged mice) × 100.
Recognition of recombinant proteins by bovine sera
Microtiter plates (Immunolon II) were coated with anti-FMDV
rabbit serum (1/3000) in carbonate-bicarbonate buffer, pH 9.6,
at 4°C overnight. After washing and blocking, known amounts
of purified iFMDV and the same amount of recombinant
proteins or mock transfected cell lysates were added and
incubated on plates at 37°C for an hour. Plates were then
incubated with sera from bovines vaccinated with the
conventional FMD vaccine, followed by horseradish
A Novel Strategy for FMDV Empty Capsids Production
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peroxidase-conjugated anti-bovine goat serum (KPL). O-
phenylenediamine-H2O2 was used as substrate. The reaction
was stopped with sulfuric acid 12%. Percentage of positivity
was calculated as (A492 from recombinant protein or mock
lysate/A492 from iFMDV) × 100.
Results
The capsid precursor P12A and the protease 3C were
cloned together (pTT5-P12A3C) and the structural proteins
were cloned separately (pTT5-VP0, pTT5-VP3 and pTT5-VP1)
(Figure 1).
Suspension growing 293-6E cells were transfected with
pTT5-P12A3C or with the combination of pTT5-VP0, pTT5-VP3
and pTT5-VP1. Forty-eight hours post transfection (hpt) cells
were harvested, resuspended in lysis buffer and analyzed for
recombinant protein expression.
Western blot assay of the cell lysates showed that when the
pTT5-P12A3C plasmid was used for transfection, the P12A
capsid precursor was successfully cleaved by protease 3C into
the structural proteins VP0 (37 kDa), VP3 (23 kDa) and VP1
(23 kDa) (Figure 2). The same band pattern was detected in
the lysates of cells transfected with the plasmids encoding the
individual structural proteins, confirming that the structural
proteins were also successfully expressed.
The highest recombinant protein yield was obtained in the
lysates of 293-6E cells transfected with pTT5-P12A3C. By
using this strategy, the recombinant protein yield was 3 mg per
liter of cell culture, measured by ELISA. Despite the absence of
protease 3C, when cells were co-transfected with pTT5-VP0,
pTT5-VP3 and pTT5-VP1, expression levels were 10 times
lower than the ones obtained with pTT5-P12A3C.
In order to determine if the expressed proteins assembled
into subviral particles, cell lysates were analyzed by ELISA
using four monoclonal antibodies (MAbs) directed against
conformational epitopes of the virus [29]. The four MAbs
Figure 1.  Schematic representation of FMDV genomic
fragments cloned into the pTT5-vector.  
doi: 10.1371/journal.pone.0072800.g001
assayed reacted with cell lysates when the plasmid pTT5-
P12A3C was used for transfection (Figure 3). Only three MAbs
reacted with cell lysates when the plasmids encoding the
individual structural proteins were used for transfection.
To further characterize the recombinant proteins, lysates of
293-6E cells transfected with pTT5-P12A3C were loaded onto
45-15% sucrose gradients. Inactivated FMDV A/Arg/01 was run
in the same conditions as positive control. Lysates of cells
Figure 2.  Western blot analysis of recombinant structural
proteins.  Lysates of cells transfected with pTT5-P12A3C, co-
transfected with pTT5-VP0, pTT5-VP3 and pTT5-VP1 or mock
transfected were analyzed by SDS-PAGE and Western blot
using anti-FMDV guinea pig serum (1:500). iFMDV was used
as positive control. The expected migration positions of VP0,
VP3 and VP1 are indicated by arrows.
doi: 10.1371/journal.pone.0072800.g002
Figure 3.  Antigenic reactivity of recombinant structural
proteins.  Lysates of cells transfected with pTT5-P12A3C, co-
transfected with pTT5-VP0, pTT5-VP3 and pTT5-VP1, mock
transfected cells or purified iFMDV were analyzed by ELISA
with four MAbs (1–5,2–4,3–2,3–3) directed against
conformational epitopes of FMDV. Error bars are standard
deviation from three independent experiments.
doi: 10.1371/journal.pone.0072800.g003
A Novel Strategy for FMDV Empty Capsids Production
PLOS ONE | www.plosone.org 4 August 2013 | Volume 8 | Issue 8 | e72800
transfected with pTT5-P12A3C showed a main peak of
antigenic material that sedimented at the same rate as native
empty capsids (75S). Antigenic peaks in the fractions
corresponding to pentamers (12S) and protomers (5S) were
also identified (Figure 4).
For animal studies, 200 ml of cell culture were transfected
with pTT5-P12A3C or with pTT5-P12A and harvested 48 hpt.
Western blot assay showed that the P12A precursor was
successfully expressed (83 kDa) and that a similar recombinant
protein yield compared to the use of pTT5-P12A3C was
achieved, based on band intensity (Figure 5). The capsid
precursor P12A was expressed in order to elucidate whether
the correct processing of the capsid precursor P12A and
further assembly into subviral particles was a critical feature to
elicit a protective immune response in mice. A significant
difference was observed in the immune response elicited in
mice vaccinated with proteins expressed from pTT5-P12A3C or
pTT5-P12A, confirming that the correct cleavage of P12A by
protease 3C and assembly of the structural proteins is critical
to achieve a protective immunity. Mice inoculated with the
lysates of cells transfected with pTT5-P12A3C and with
inactivated FMDV induced high antibody serum titers at 14 dpi
that increased after booster immunization (Figure 6). All these
mice were protected against viral challenge (Table 1). Mice
inoculated with the lysates of 293-6E cells transfected with
pTT5-P12A and lysates of mock transfected cells, showed low
serum titers that did not increase after booster immunization.
However, a 43% of protection was obtained in mice inoculated
with the recombinant capsid precursor P12A. Mice inoculated
with the mock transfected cell lysates and those that did not
received treatment, showed viraemia.
Finally we proceeded to evaluate whether recombinant
empty capsids were recognized by sera from cattle vaccinated
Figure 4.  Assembly of recombinant structural proteins
into subviral particles.  Lysates of cells transfected with
pTT5-P12A3C, mock transfected cells or iFMDV were loaded
onto 45-15% sucrose gradients. Fractions were collected and
analyzed by solid phase ELISA. Fractions of iFMDV were
measured at 260 nm for RNA detection. The known positions
of the FMDV virions (146S), empty capsids (75S), pentamers
(12S) and protomers (5S) are indicated.
doi: 10.1371/journal.pone.0072800.g004
with a commercial vaccine against FMDV. Sera from
vaccinated bovines were assayed for the recognition of iFMDV,
recombinant empty capsids and mock transfected cell lysates
in a parallel ELISA assay. Sera from vaccinated bovines
reacted similarly against recombinant empty capsids and
iFMDV, and did not react with mock cell lysates (Figure 7).
Figure 5.  Western blot analysis of recombinant proteins
produced after transfection with pTT5-P12A3C or with
pTT5-P12A.  Lysates of cells transfected with pTT5-P12A3C,
pTT5-P12A or mock transfected were analyzed by SDS-PAGE
and Western blot using anti-FMDV guinea pig serum (1:500).
iFMDV was used as positive control. The expected migration
positions of P12A, VP0, VP3 and VP1 are indicated by arrows.
doi: 10.1371/journal.pone.0072800.g005
Figure 6.  Analysis of humoral response of BALB/c mice
immunized with recombinant proteins.  The results were
obtained from the average of seven sera in each group. Mean
± SD sample is shown.
doi: 10.1371/journal.pone.0072800.g006
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Sera from non-vaccinated bovines were also assayed, showing
no reactivity with either the virus or recombinant empty capsids
(data not shown).
Discussion
When designing a new generation vaccine against FMDV,
success not only depends on the immunogenicity of the novel
vaccine, but also on the feasibility of the production strategy to
be adopted by industrial laboratories. This feasibility depends
on simplicity, scalability and versatility of the novel strategy
proposed. This study was undertaken to evaluate TGE in
serum-free suspension-growing 293-6E cells for the production
of a recombinant subunit vaccine against FMD. For this
purpose, plasmids encoding FMDV capsid precursor (P12A)
together with protease 3C or encoding structural proteins
individually (VP0, VP3 and VP1) were generated and
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a Number of protected mice over number of challenged mice. Protection was
established as absence of viremia 24 h post challenge.
b The percentage of protection is calculated as (n° of animals without viremia/n° of
challenged animals) × 100.
transfected into 293-6E cells. The highest expression levels
were achieved when pTT5-P12A3C plasmid was used for
transfection. These levels are similar to the ones obtained in
the vaccine facilities after infection of BHK-21 cells,
representing an attractive yield to industrial laboratories [31].
P12A3C was also transiently expressed in BHK-21 cell
monolayers using Lipofectamine 2000 (Invitrogen), but the
yield was about 100 times lower when using pCI-neo vector
[28]. Thus, the use of suspension-growing 293-6E cells in
combination with the pTT5 vector is the key feature in this
proposed method for the production of high amounts of FMDV
recombinant proteins. This may be due to high cellular
densities achieved in cell culture plus the episomal
maintenance of the pTT5 plasmid in the transfected cells.
Moreover, the use of serum-free medium and PEI as
transfection reagent turns the proposed strategy into a cost-
effective technology.
Even though protease 3C has a deleterious effect on protein
expression [20,32], the strategy of co-transfecting cells with
plasmids encoding the individual structural proteins (VP0, VP3
and VP1), resulted in lower expression levels compared to the
use of the P12A3C expression cassette. This result is in
accordance with Brautigam et al. [33] that reported the same
result for poliovirus using the baculovirus expression system
and could be related to mRNA instability. However, further
studies should be done in order to confirm this hypothesis. The
recombinant proteins expressed in 293-6E cells after co-
transfection with pTT5-VP0, pTT5-VP3 and pTT5-VP1
assembled into structures that were not recognized by one of
the MAbs directed against conformational epitopes of the virus.
Thus, at least, one conformational epitope is absent. This
difference in the assembly could be attributed to a tempo-
spatial factor. Probably when the P12A3C expression cassette
Figure 7.  Recombinant empty capsids recognition by sera from vaccinated bovines.  Percentage of positivity of bovine sera
analyzed by ELISA for the recognition of recombinant empty capsids and mock transfected cell lysates. Percentage of positivity was
calculated as (A492 from recombinant protein or mock lysate/A492 from iFMDV) × 100. Each pair of bars represents the sera from an
individual animal.
doi: 10.1371/journal.pone.0072800.g007
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is used for transfection, after the proteolitic cleavage of the
capsid precursor, the structural proteins are at the same time in
a balanced concentration and close enough to interact properly
assembling in the correct way. This issue remains to be further
analyzed and could contribute to elucidate some steps of the
assembly of picornavirus structural proteins that are
incompletely understood. Thus, both the levels of expression
and the quality of the recombinant protein are improved when
cells are transfected with the P12A3C expression cassette.
It has been recently reported that optimal production of VP0,
VP3 and VP1 in BHK-21 cells is achieved with reduced levels
of protease 3C expression relative to P12A, compared to the
use of P12A3C expression cassette [34]. However, when we
co-transfected cells with 5% (w/w) of pTT5-3C and 90% of
pTT5-P12A we achieved lower expression levels compared to
the use of 90% of pTT5-P12A3C (data not shown).
Recombinant proteins expressed in 293-6E cells after
transfection with pTT5-P12A3C assembled into empty capsids
(75S) as well as pentamers (12S) and protomer (5S). These
structures triggered an immune response, similar to the one
elicited by the same amount of inactivated virus, that
surpassed the viral challenge in a mice model. When
recombinant capsid precursor P12A was used to immunize
mice, no specific antibody response was detected. Since
equimolar amounts of recombinant proteins were used for
immunization, the only difference between both groups is the
cleavage of the capsid precursor by protease 3C and further
assembly into subviral particles of the structural proteins. This
result, in agreement with previous studies, highlights the
importance of the use of empty capsids when designing a FMD
recombinant vaccine.
Despite the fact that mice inoculated with the recombinant
capsid precursor P12A showed low serum titer levels that did
not increase after booster immunization, 43% of protection was
achieved. This protection could be due to cellular immunity, as
already suggested [35] and should be further investigated.
Recombinant viral structures were recognized by sera from
vaccinated bovines, further suggesting that recombinant
structures mimic the authentic virus.
Our studies strongly suggest that TGE is a very promising
approach for the production of a subunit vaccine against
FMDV. Several alternative strategies to conventional vaccines,
such as subunit vaccines, recombinant viral vectors and DNA
vaccines, have been reported [36]. Most of these strategies are
based on the use of the P12A3C expression cassette, either
alone [13,37] or co-expressing different cytokines [16,38] or
with modifications in the sequence in order to confer more
stability to the capsid structure or less toxicity of protease 3C
on the cells [12]. The production of recombinant empty capsids
by TGE is the most similar strategy to the production process
and the final formulation of the currently used inactivated
vaccine. Instead of infecting suspension-growing BHK-21 cells,
293-6E cells should be transfected with PEI-DNA complexes
eliminating the need of high biosafety containment facilities.
The proposed technology is robust, inexpensive, easy to
perform and scalable. Moreover, mammalian cells are the
dominant system for the production of vaccines and therapeutic
proteins. Thus, they represent a well known system for the
industrial laboratories. The largest volume for TGE reported so
far has been 100L [39]. Therefore, even though it would be
difficult to replace the current inactivated vaccine in endemic
countries because many doses are needed, FMD-free
countries could produce emergency doses by TGE. This
vaccine offers the advantage of safe production and fulfills the
need to be able to demonstrate the re-establishment of the
FMD-free status for trade purpose because final formulations
are free from non-structural proteins and are compatible with
so called DIVA tests that Differentiate Infection in Vaccinated
Animals. Thus, with this technology FMD-free countries could
adopt “vaccination to live” policies in case an outbreak occurs.
The absence of serum in the cell culture diminishes the cost of
the whole process and reduces the risk of adventitious virus to
be present in the vaccine. Since only a cloning step is needed
before production starts, TGE could allow the rapid
incorporation of new field strains in the vaccine formulation and
the production of those serotypes and subtypes difficult to
adapt to cell culture. Furthermore, rationally designed
modifications in the encoding sequences of the capsid
precursor and protease 3C to stabilize the capsid structure or
diminish the toxic effect of the protease, could be easily
evaluated by TGE.
Traditionally, TGE evolved as an alternative approach to the
generation of stable cell lines for the rapid production of mg of
proteins for academia and preclinical studies. However, for
toxic proteins -when the development of stable high expressing
clones is not possible [21]- TGE seems to be the only rational
and possible approach [24,25]. Moreover, with these proteins
TGE can become a production system in its own right.
No therapeutic proteins produced by TGE have gain
approval until now. In contrast with human vaccines, veterinary
vaccines can be evaluated in target species making it easier to
achieve the regulatory requirements needed for approval.
Therefore, TGE represents a powerful and versatile technology
for the production of recombinant FMDV empty capsids for
vaccine development.
Future experiments should evaluate improvements in
expression levels (for example by codon optimization or down
regulation of protease 3C) and also explore the versatility of the
technology for the expression of empty capsids of other
serotypes of the virus. Also, additional studies are needed to
investigate the immunogenicity of recombinant subviral
particles in cattle.
Conclusion
In conclusion, the use of TGE for the production of
recombinant FMDV empty capsids represents a promising
strategy for the development of a new generation vaccine.
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